Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Research square·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma.

Cancers·2026
Same author

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

Nature communications·2026
Same author

Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.

Cancer research communications·2026
Same author

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: May 24, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Cellular immunotherapy for soft tissue sarcomas.

Steven Eric Finkelstein1, Mayer Fishman, Anthony P Conley

  • 1H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. sfinkels@rtsx.com

Immunotherapy
|March 10, 2012
PubMed
Summary
This summary is machine-generated.

Immunotherapy offers a promising complementary approach for treating rare soft tissue sarcomas, showing potential for long-term antitumor activity against both local and systemic disease. This review explores innovative vaccine strategies in development for these challenging cancers.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: May 24, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Soft tissue sarcomas are rare cancers with limited treatment advancements in recent decades.
  • Current treatments including surgery, chemotherapy, and radiation have shown insufficient progress for metastatic disease.

Purpose of the Study:

  • To review emerging immunotherapeutic strategies for soft tissue sarcomas.
  • To highlight the potential of immunotherapy as a complementary treatment modality.

Main Methods:

  • Review of current literature on immunotherapeutic investigative strategies.
  • Focus on tumor, antigen, and dendritic cell vaccine approaches.

Main Results:

  • Immunotherapy presents a promising avenue for managing soft tissue sarcomas.
  • Antitumor activity can impact both local-regional and systemic disease.
  • Potential for prolonged therapeutic effects.

Conclusions:

  • Investigational immunotherapies, particularly vaccine strategies, are under development for soft tissue sarcomas.
  • Immunotherapy could offer a novel approach to complement existing treatments for these rare neoplasms.